Oxford BioTherapeutics Ltd has formed a collaboration with Seattle Genetics Inc to jointly discover antibody-drug conjugates (ADC) for cancer. ADCs are antibodies attached by a linker to a cytotoxic drug and designed to kill cancer cells. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
